Reckamp, Karen L.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 8,447

EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 500

Non–Small Cell Lung Cancer, Version 6.2015

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 478

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., Perol, M., Oxnard, G. R., Kosco, K., Croucher, P., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 287

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 146

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Reckamp, K. L., Giaccone, G., Camidge, D. R., Gadgeel, S. M., Khuri, F. R., Engelman, J. A., Koczywas, M., Rajan, A., Campbell, A. K., Gernhardt, D., et al. (2014) · Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 144

The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers

Kim, J. Y., Sun, V., Raz, D. J., Williams, A. C., Fujinami, R., Reckamp, K., Koczywas, M., Cristea, M., Hurria, A., & Ferrell, B. (2016) · Lung Cancer

Cancer survivorship and careNursing care and research

Cited by 48

A Multimedia Self-management Intervention to Prepare Cancer Patients and Family Caregivers for Lung Surgery and Postoperative Recovery

Sun, V., Raz, D. J., Ruel, N., Chang, W., Erhunmwunsee, L., Reckamp, K., Tiep, B., Ferrell, B., McCorkle, R., & Kim, J. Y. (2017) · Clinical Lung Cancer

Cancer survivorship and careNursing care and research

Cited by 47

Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation

Patel, S. P., Pakkala, S., Pennell, N. A., Reckamp, K. L., Lanzalone, S., Polli, A., Tarazi, J., & Robert-Vizcarrondo, F. (2020) · The Oncologist

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 34